弓形虫可溶性抗原混合液延长小鼠移植心脏存活时间

目的 探讨弓形虫可溶性抗原混合液(STAgs)延长小鼠移植心脏存活时间的作用及其作用机制.方法 通过在冰浴中超声粉碎弓形虫速殖子制备弓形虫STAgs.实验分为3组,每组受者9只.STAgs组和急性排斥反应(AR)组:供者为Balb/c小鼠,受者为C57BL/6小鼠,移植前4 d两组受者分别皮下注射STAgs 5μg和磷酸盐缓冲液100μl,同系对照组供、受者均为C57BL/6小鼠,术前未进行任何处理.分组后建立小鼠颈部异位心脏移植模型.术后观察移植心脏存活时间,术后第7天每组处死3只受者,获取移植心脏行病理学检查观察排斥反应,采用免疫组织化学检测移植心中CD4+和CD8+T淋巴细胞.结果 同系移植组在观察终点100 d时均存活,AR组和STAgs组移植心脏存活时间分别为(6.7±0.5)和(70.8±3.5)d,3组间两两比较,差异均有统计学意义(P＜0.05).术后第7天,同系移植组、AR组和STAgs组移植心排斥反应分级分别为0级、Ⅲ～Ⅳ级和0～Ⅰ级;免疫组织化学检测显示STAgs组CD4+和CD8+T淋巴细胞比例明显少于AR组,差异有统计学意义(P＜0.05).结论 弓形虫STAgs能显著延长小鼠移植心脏的存活时间,减轻移植心脏的排斥反应,县体机制可能与弓形虫STAgs可影响TH1/TH2比例相关,也可能通过刺激机体产生脂氧素A4抑制树突状细胞活化发挥作用.

Abstract：

Objective To investigate the effects of T. gondii soluble tachyzoite antigen (STAgs) on the survival time of mouse heart allograft and the possible mechanism. Methods The STAgs were prepared by pulverizing T. gondii tachyzoite with ultrasound on ice. Cervical heterotopic heart transplantations were done by using Balb/c mice as donors, and C57BL/6 mice as recipients.The recipients were classified randomly into three groups: syngeneic group, acute rejection group and STAgs-treated group. The recipients in acute rejection group and STAgs-treated group were injected subcutaneously with 0. 1 ml PBS and 0. 1 ml (5 μg) STAgs at the 4th day before transplantation respectively, and those in syngeneic group were not subjected to any treatment. The grafts were observed daily by cervical palpation, and the total cessation of cardiac contraction was defined as the endpoint. The heart allografts were harvested at the 7th day after transplantation for pathological examination and immunohistochemical staining for CD4+ T, CD8+ T. Results The recipients in syngeneic group were all alive at the 100th day after transplantation. The average survival time in acute rejection group and STAgs-treated group was (6.7± 0.5) days and (70.8± 3.5) days,respectively (P＜0.05). HE staining showed that the rejection on the 7th day after transplantation in syngeneic group, acute rejection group and STAgs-treated group was fallen into 0 degree, Ⅲ-Ⅳ degree and 0- Ⅰ degree, respectively. Immunohistochemical staining revealed that the CD4+ T and CD8+T were markedly down-regulated in STAgs-treated group as compared with those in acute rejection group. Conclusion T. gondii STAgs can significantly prolong the survival time of mouse heart allograft and inhibit the rejection probably by changing the ratio of TH1/TH2, or inhibiting the effect of dendritic cells by inducing the lipoxin A4.     

DDR 2基因突变与肺癌发生发展的相关性研究

【目的】探讨DDR2基因突变与肺癌发生的相关性,为肺癌的靶向治疗提供理论依据。【方法】选取上海交通大学附属胸科医院2010年5月至2012年5月确诊的200例肺癌患者及同期100例正常肺组织标本,分别纳入观察组及对照组,分析两组DDR2基因测序结果差异,并探讨基因突变与肺癌发生的相关性。【结果】观察组DDR2基因突变率为23．0％（46/200）,对照组突变率为1．0％（1/100）,观察组突变率显著高于对照组,且两组相比较差异有显著性（P ＜0．05）;肺鳞癌 DDR2基因突变率为51．4％（17/39）,显著高于腺癌、鳞腺癌等其他病理分型,且差异均有显著性（P ＜0．05）;DDR2基因突变率与肿瘤分期无相关性（P ＞0．05）。【结论】DDR2基因突变是肺鳞癌发生的关键因素,但对肺癌的进展结果无明显影响。     

肺腺癌中Krüppel样因子7的表达及与患者临床特征和预后的相关性

目的 探讨肺腺癌中Krüppel样因子7(KLF7)的表达及与患者临床特征和预后的相关性。方法 分析80例肺腺癌患者肺腺癌组织中的KLF7表达情况,根据KLF7表达情况分为KLF7高表达组（54例）和KLF7低表达组（26例）,比较KLF7高表达组与KLF7低表达组患者的临床特征,分析KLF7表达与临床特征及预后的相关性。结果 80例肺腺癌患者无病生存率为70.00%(56/80),总生存率为77.50%(62/80)。KLF7高表达组与KLF7低表达组患者年龄、分化程度、胸膜侵犯情况、组织学亚型、大体类型比较,差异均无统计学意义（P﹥0.05）;KLF7高表达组与KLF7低表达组患者吸烟情况、肿瘤体积、淋巴结转移情况、TNM分期比较,差异均有统计学意义（P﹤0.01）。Spearman相关分析结果显示,KLF7表达与吸烟、肿瘤体积、淋巴结转移、TNM分期均呈正相关,与无病生存率和总生存率均呈负相关（P﹤0.01）。结论 KLF7表达与肺腺癌的发生、发展及预后存在一定关联,临床可根据肺腺癌患者的KLF7表达情况,判断其病情进展情况,并预测其预后,以便临床及时帮助患者制订针对性的治疗方案...